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H I G H L I G H T S
• All naloxone formulations except Narcan Nasal Spray increased in price since 2006.
• Increases ranged from 244% to 3797% across these formulations.
• Increased demand, a drug shortage, and limited competition may have contributed to price increases.








A B S T R A C T
Anecdotal evidence indicates that naloxone prices have risen in recent years, but limited research has examined
the magnitude of these increases and potential causes. We contribute nationally representative evidence to help
answer each of these questions, including wholesale pricing data from a proprietary drug sales database span-
ning January 2006 to February 2017. We find that all formulations of naloxone increased in price since 2006
except for Narcan Nasal Spray. These cumulative increases totaled 2281% for the 0.4 MG single-dose products,
244% for the 2 MG single-dose products, 3797% for the 4 MG multi-dose products, and 469% for the 0.4 MG
Evzio auto-injector. We believe that increased demand for naloxone from the opioid epidemic may explain the
more gradual price increases for the 0.4 MG single-dose and 4 MG multi-dose products prior to 2012. On the
other hand, we believe that the sudden, sustained prices increases occurring for all of the products since 2012
may be the result of a drug shortage for the 0.4 MG single-dose products and the fact that each naloxone product
has historically been sold by only a single competitor.
1. Introduction
Drug overdose has become the leading cause of accidental death in
the United States for people ages 25 to 64, with opioids implicated in
nearly two-thirds of these cases (“Ten Leading Causes of Death and
Injury,”; Rudd, Aleshire, Zibbel, & Gladden, 2016). A key strategy for
reducing the number of deaths due to opioid overdoses has been to
expand access to the opioid antidote naloxone. The U.S. Surgeon Gen-
eral recently recommended that people who interact with those at
elevated risk of opioid overdose obtain naloxone and learn how to
administer it (Surgeon General of the United States). Likewise, many
states have enacted legislation allowing naloxone to be dispensed at a
pharmacy without an individual prescription (“Comprehensive
Addiction and Recovery Act of 2016”; National Conference of State
Legislatures; The White House n.d).
At the same time, a growing body of anecdotal evidence suggests
that the price of naloxone suddenly increased by more than 50% in
recent years (Goodman, 2014; Gupta, Shah, & Ross, 2016; Jacobs,
2016; “Price Soars For Key Weapon Against Heroin Overdoses, 2015”).
When combined with rising insurance deductibles, (Kaiser Family
Foundation and the Health Research, & Educational Trust, September
14, 2016) this increase has raised concerns among stakeholders that
patients will no longer be able to afford the drug (Harm Reduction
Coalition, 2015; “Senator Leahy & Leading Senators Demand Answers
About Outrageous Price Hike For Lifesaving Anti-Opioid Drug”).
To make an informed decision about how to respond to these price
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increases, it is important to answer two questions. First, is the price of
naloxone increasing, and if so, by how much? Published literature on
this topic appears to be scarce. Only one study measures naloxone
prices, and in doing so relies on companies' self-reported list prices from
a drug compendium (Gupta et al., 2016). Second, if the price of na-
loxone is increasing, why is this happening? To our knowledge, no
published studies have examined the economic factors that may be
behind these increases.
Our study provides nationally representative evidence to help ad-
dress these two questions. We use pharmaceutical sales data from a
proprietary drug sales database, based on actual wholesale purchases of
naloxone, to assess whether prices for the drug have increased, and how
large these increases have been. We also examine whether certain
economic factors, such as raw material costs, drug shortages, increases
in demand, or limited competition among naloxone manufacturers
appear to be associated with price increases.
2. Materials and methods
2.1. Data source
We rely on proprietary data from IQVIA to calculate national trends
in wholesale naloxone prices from January 2006 to February 2017. The
IQVIA, National Sales Perspective (NSP) (IQVIA, 2017 January
2006–February 2017) measures invoice transactions between whole-
salers and both retail and non-retail settings of care, such as pharmacies
and hospitals (see the Database Description in the Supplemental
Materials for more information); this dataset generally excludes dona-
tions and direct manufacturer sales to end buyers that do not occur
through a wholesaler. IQVIA estimates that the NSP data capture 88%
of wholesale purchases of prescription drugs, and applies a projection
methodology to obtain national estimates (IQVIA, March, 2016).
2.2. Sample
We focus on single-ingredient naloxone hydrochloride, and divide
the market into distinct formulations to examine whether price levels
and trends vary between different products. We define formulations by
the dosage form and the number of MG of naloxone contained in the
product, equal to the strength multiplied by the size of the package. For
example, a 2mL vial of naloxone with a strength of 1mg/mL would be
counted as a 2 MG product.
The six resulting formulations include single-dose injections, which
are available as 0.4 MG and 2 MG vials or syringes; multi-dose injec-
tions, which are available as 4 MG vials; nasal sprays (brand name:
Narcan Nasal Spray), which are available as 4 MG devices; and auto-
injectors (brand name: Evzio), which are available as 0.4 MG and 2 MG
syringes.
2.3. Measures
We calculate average prices by dividing total sales in dollars, un-
adjusted for inflation, by the total number of MG of naloxone sold
(equal to the number of MG in the product times the number of injec-
tions, sprays, or auto-injectors sold). This allows us to compare prices
across formulations that deliver different doses, and which may be
priced at different levels. These prices exclude any discounts that are
not recorded on a wholesaler's invoice, such as rebates that a manu-
facturer provides directly to an end buyer.
3. Results
Fig. 1 shows the monthly price of naloxone for all formulations
except for Evzio auto-injectors. In the latest month of data (February
2017), the 0.4 MG single-dose products cost $35.00/mg ($14.00/in-
jection), the 2 MG single-dose products cost $14.59/mg ($29.18/
injection), the 4 MG nasal spray (Narcan Nasal Spray) cost $13.82/mg
($55.28/spray), and the 4 MG multi-dose products cost $25.72/mg
($102.88/injection). On a per MG basis, it appears that Narcan Nasal
Spray priced itself comparably to the 2 MG single-dose products, which
can also be used as a nasal spray when attached to a mucosal atomizer
device (Harm Reduction Coalition, 2017).
In terms of price trends, each of the formulations shown in Fig. 1,
besides the nasal spray, rose in price since 2006. The 0.4 MG single-
dose formulations increased from $1.47/mg to $35.00/mg (2281%),
the 2 MG single-dose formulations increased from $4.24/mg to $14.59/
mg (244%), and the 4 MG multi-dose formulations increased from
$0.66/mg to $25.72/mg (3797%). For the 2 MG products, the increase
occurred sharply in late 2014, while the other two formulations had
been increasing steadily for many years until experiencing sharp price
increases during 2012 to 2014. Since early 2015, however, it appears
that the price of each of these products has stabilized, with smaller
increases, and even in some cases decreases in price.
Fig. 2 shows the monthly price for naloxone auto-injectors, which
are sold under the Evzio brand name. Note that this graph starts from
July 2014, which was the first month of sales in the NSP data (Evzio
was first approved in April 2014 (Food and Drug Administration, April
3, 2017)). Prices for these formulations were much higher. In the latest
data, Evzio was priced at $3955.25/mg and $983.80/mg for the 0.4 MG
Fig. 1. Monthly price per MG of naloxone by formulation, excluding auto-in-
jectors; January 2006 to February 2017.
Fig. 2. Monthly price per MG of naloxone auto-injectors; July 2014 to February
2017.
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and 2 MG products respectively ($1582.10 and $1967.70 per auto-in-
jector). While the 2 MG auto-injector has only been sold since January
2017 and has had a steady price, the 0.4 MG auto-injector
sharply raised its price in early 2016, with an aggregate increase from
$695.36/mg to $3955.25/mg (469%) since its launch in July 2014.
For the raw data used to create both Figs. 1 and 2, see Table A in the
Supplemental Materials.
4. Discussion
The price of naloxone does seem to have increased across most
formulations of the drug (except for Narcan Nasal Spray). Furthermore,
these increases outpaced overall inflation in pharmaceutical prices,
which was 99% from January 2006 to February 2017 and 24% from
July 2014 to February 2017 (Bureau of Labor Statistics, 2017). We
examine four economic rationales that may explain these rising prices:
three types of external shocks (raw material prices, supply disruptions,
and increased demand), as well as business decisions resulting from
limited competition.
4.1. Raw material prices
We reviewed internal FDA data that track the price and volume of
bulk naloxone raw material imports into the United States, as self-re-
ported by importers (“Food and Drug Administration. Office of
Regulatory Affairs Reporting Analysis and Decision Support System
(ORADSS),” January 2011 to September 2017). The price of naloxone
raw materials has remained relatively stable since 2011 at around
$0.01 to $0.02 per MG, or less than one-thousandth of the price of the
finished products. This is consistent with other anecdotal evidence that
naloxone raw materials are inexpensive (Jacobs, 2016).
4.2. Supply disruptions
We used archives of FDA's public drug shortages website, main-
tained by the Wayback Machine, to search for naloxone shortages be-
tween August 2000 and April 2017 (Food and Drug Administration).
We found two shortages listed, which appear to have been driven by
issues with the 0.4 MG single-dose formulation: one from June 2010 to
December 2010, and the other from February 2012 to July 2013. The
second shortage appears to coincide with some of the sharp price in-
creases for the 0.4 MG single-dose and the 4 MG multi-dose products
seen in Fig. 1.
4.3. Increased demand
We evaluated surrogates for naloxone demand and found that this
market is likely facing steadily increasing demand due to the opioid
epidemic.
We observe that deaths involving opioid overdoses have risen
steadily since 2006, from 6 per 100,000 to about 10.5 per 100,000 by
2015 (Centers for Disease Control and Prevention, 2016). In response to
this trend, the Harm Reduction Coalition pledged to increase the
number of doses of naloxone distributed to community groups from
140,053 doses in 2013 to 400,000 doses in 2016 (The White House;
Wheeler, Jones, Gilbert, & Davidson, 2015).
However, steadily increasing demand over many years would also
imply a steadily increasing price. While this was true for the 0.4 MG
single-dose and 4 MG multi-dose products up until 2012, the 2 MG
single-dose and 0.4 MG auto-injector experienced primarily sudden
price increases, and at different points in time from each other.
4.4. Limited competition
One possible explanation for a sudden price increase is that a
company finds itself with few competitors for a medically important
drug and makes a business decision to raise prices.
In the naloxone market, conditions existed that may have provided
firms with the leverage needed to raise prices. Each formulation was
historically sold by a single company – Hospira for the 0.4 MG single-
dose and 4 MG multi-dose products, Amphastar for the 2 MG single-
dose product, Kaleo for the 0.4 MG and 2 MG auto-injectors, and Adapt
for the 4 MG nasal spray (Rosenberg, 2015). Although these products
were at least partial substitutes for one another, differences in admin-
istration meant that some users may not have been willing to switch if
prices increased.
We were unable to estimate the extent to which naloxone producers
could have unilaterally raised prices, since we lacked data on firms'
demand curves and production costs. However, we note that the 0.4 MG
and 2 MG auto-injectors currently appear to be priced comparably to
what previous research estimates as the maximum cost-effective level of
a two-dose naloxone kit used by lay people – $4480/kit in 2012 dollars
(Coffin & Sullivan, 2013).
While conditions in the naloxone market may have allowed for
unilateral price increases, companies also appear to have had this op-
tion for many years without exercising it. It is possible that firms may
have become more willing to increase prices given the increase in de-
mand highlighted in Section 4.3, the higher launch price for Evzio, and
the generally greater frequency of large price increases in the generic
drug industry (United States Government Accountability Office, August,
2016).
For the list of companies holding active FDA approvals for naloxone
as of April 3, 2017, see Table B in the Supplemental Materials.
5. Conclusions
The price of naloxone appears to have risen since 2006 for all for-
mulations except for Narcan Nasal Spray. We believe that a drug
shortage, increased demand, and limited competition have all con-
tributed to these increases.
Our pricing metrics, while a useful approximation, are limited in
three ways. One challenge is that they do not adjust for bulk discounts,
which may lead to lower prices in hospitals and other larger settings of
care than our data indicate. In addition, our metrics do not include any
discounts or rebates that may be offered to institutional buyers, such as
the Department of Veterans Affairs. Finally, these prices do not account
for donations or direct sales by manufacturers to organizations such as
schools or first responders.
Additional research is needed to further characterize the naloxone
market and to identify whether price increases have the potential to
affect patient access. This could include estimating the cost of manu-
facturing naloxone, calculating whether or how much patients or other
purchasers pay out of pocket for the drug, and evaluating how willing
patients are to cease use or switch to other formulations as prices in-
crease.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.addbeh.2018.05.006.
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